PRL and neoplasm: A patient with a PRL secreting tumor treated with EVE 10mg + octreotide showed decreased PRL levels (454 ng/ml to 253 ng/ml; 55% reduction) after an initial 3 months of EVE therapy; however, PRL level gradually increased to its previous level by 5 months following initiation of EVE therapy (25).